Introduction
============

The role of brown and white adipocytes in metabolism
----------------------------------------------------

The continuous rise in the incidence of world-wide obesity reflects the persistent lack of efficient treatment strategies. Obesity results when energy intake exceeds energy expenditure on a regular basis (National Institutes of Health, [@B37]; World Health Organization, [@B68]). Excess calories are stored as single intracellular triacylglycerol (TG) droplets in white adipose tissue (WAT), the organism's largest reserve of energy. Conversely, brown adipose tissue (BAT) shifts the energy balance toward expenditure. BAT dissipates the energy resulting from the catabolism of glucose and fatty acids using uncoupling protein 1 (UCP1)-mediated thermogenesis. In rodents kept in cold, despite comprising only a few percent of the body weight, BAT may reduce more than 50% of all the oxygen inhaled/food consumed and hence, dissipate chemical energy of same magnitude (Cannon and Nedergaard, [@B7]; Nedergaard et al., [@B39]).

As expected from their distinct physiological roles, WAT and BAT were shown to derive from different precursor cells (Seale et al., [@B53]). While WAT cells originate in the lateral plate mesoderm, from pericyte-like cells associated with blood vessels, BAT-cells share with myocytes a common Myf5+ precursor originated in the dermomyotome derived from the paraxial mesoderm (Seale et al., [@B53]). The transcriptional regulator PRDM16 (PRD1--BF1--RIZ1 homologous domain containing 16) was shown to determine the brown fat fate of the Myf5-positive precursors (Seale et al., [@B53]). Additionally, UCP1-positive cells can arise in WAT under certain conditions (cold exposure, for example). These cells have been designated as "brite" and although they express UCP1 at much lower levels than BAT adipocytes, they do not possess many features of "classic" BAT-cells (Waldén et al., [@B66]). Besides Myf5, present in BAT but not "brite precursors," the molecular markers homeobox C9 (Hox9) and Zinc fingers in the cerebellum 1 (Zic1) also display adipose depot-dependent expression. Zic1 is only expressed in "classic" BAT while Hox9 is expressed in both "brite" and WAT, but not BAT (Waldén et al., [@B66]).

BAT detection in humans
-----------------------

Although it was long considered that the prominent BAT depots of newborns were progressively lost with age, to end up being supposedly absent from human adults, a combination of positron emission and computer tomography (PET/CT) data from a number of studies originally done to detect metabolically active tumors, recently confirmed by dedicated analyzes that a significant proportion of adult humans may actually possess significant amounts of physiologically relevant BAT (Nedergaard et al., [@B38]; Cypess et al., [@B11]; van Marken Lichtenbelt et al., [@B62]; Orava et al., [@B44]). The prevalence in pediatric patients is nevertheless, still several fold higher than in adults, although an increase in BAT may occur from childhood to adolescence in both boys and girls, as measured by CT Hounsfield Units of X-ray attenuation's (HU) and PET (Gilsanz et al., [@B17]).

Positron emission and computer tomography scans have become indisputably the gold-standard in BAT detection. However, the requirement for radiolabeled tracers limits its use. ^8^F-2-fluoro-2-deoxyglucose (F-DG) is typically used and its signal is only detected in metabolically active cells. This caveat has lead to growing interest in alternative BAT detection techniques. The feasibility of using magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS) for BAT detection is discussed elsewhere (Hu and Gilsanz, [@B23]). Of particular note, the distinction of BAT from WAT has been achieved based on their relative fat contents, which produce different signal patterns in chemical-shift--water--fat separation MRI (Hu et al., [@B25],[@B26]). Additionally, BAT and WAT were also shown to appear in non-overlapping regions in the HU scale (BAT displaying greater attenuation due to its higher vascularization and water content), even though both tissues are HU-negative and therefore distinguishable from bone and all other HU-positive soft tissues (Hu et al., [@B22]).

With the repeated detection and the general acceptance of the presence of substantial BAT in most human adults, a BAT-based route of pharmacologic intervention against obesity may now become more feasible.

Physiological relevance of BAT in humans
----------------------------------------

While there is a large quantity of studies supporting the importance of BAT metabolism to body weight in rodents, the literature is scarce in studies done in humans. Still, the inverse relationship between BMI and BAT found repeatedly in recent studies and in PET/CT scans analyzed retrospectively (see reviews by Betz and Enerbäck, [@B3] and van Marken Lichtenbelt, [@B61]), suggest that BAT could be protective against weight gain in humans.

Functionally, results from an *in vivo* analysis of adult human BAT (Orava et al., [@B44]) parallel previous findings in rodents (Bartelt et al., [@B2]). By combining PET/CT imaging, blood tests and gene expression from biopsies, human volunteers were shown to respond to cold exposure with a remarkable 12-fold increase in glucose uptake, accompanied by a doubling in BAT perfusion rate, well correlated with the subjects' metabolic rates (Orava et al., [@B44]).

The PET scans from 10 healthy men show an average BAT volume of 130 cm^3^, which corresponds to tens of grams of tissue (Saito et al., [@B52]; van Marken Lichtenbelt et al., [@B62]). When exposed to the cold (16°C for 2 h), these subjects showed increased metabolic rate, concomitant with BAT activation, reflected in the increased F-DG uptake.

Quantitative estimations of the potential metabolic impact of BAT to whole body energy expenditure in humans were extrapolated from observations in rodents and considerations on human BAT mass have been made upon analysis of F-DG PET/CT scans. Based on the maximal heat-producing capacity of 300 W/kg suggested for the mouse, 50g of maximally stimulated BAT (which can occur physiologically in humans) could dissipate daily 3--5% extra calories (Rothwell and Stock, [@B50]). This caloric deficit could translate to a loss of approximately 4 kg (∼9 pounds) in the adult yearly weight.

Though preliminary, the physiological data obtained to date points toward the potential benefits of BAT in human health. Therefore, maximizing BAT amounts and mimicking cold activation pharmacologically may constitute effective combined strategies against weight gain and the associated complications of obesity. Before getting so far, there is an urgency to develop and evaluate human brown adipocyte models as essential tools for the discovery of molecular targets to modulate BAT viability, proliferation, and activation.

BAT-derived cell lines from rodents
-----------------------------------

Hibernomas grown in p53 Knock Out mice or SV40 large T antigen transgenic mice have been used to generate immortalized murine BAT-cell lines (defined by UCP1 gene expression) such as the T37i (Penfornis et al., [@B46]), the HIB-1B (Ross et al., [@B49]), and the HB2 (Irie et al., [@B28]) cell lines (see review by Klein et al., [@B31]). These *in vitro* systems have helped acquire substantial knowledge of murine BAT biology.

The need for human adipocyte *in vitro* models
----------------------------------------------

Striking differences between the thermogenic requirements of mice and humans limit however the extent to which the findings in animals can be extrapolated to the human situation. Such differences are well illustrated by the fact that while clothed humans consume food equivalent to only about 2% of their total body energy content, a laboratory mouse living at 24°C will consume approximately 50% of its total body energy content daily, and will dedicate a large proportion of this energy to BAT heat production. If food is scarce, mice enter into torpor, an adaptive drop in body temperature and reduced metabolic rate, not seen in humans (Himms-Hagen, [@B20]). This increased need for BAT-generated heat is directly correlated with the higher surface-to-body mass ratios of smaller mammals (Himms-Hagen, [@B20]).

A number of comparative studies highlight significant differences in the genetic, metabolic, and physiologic make-up of adipose tissue among species.

For example, the genes for Type II iodothyronine deiodinase (DIO2), peroxisome-proliferator-activated receptor 1α (PGC1α) and PRDM16 have been shown to be highly enriched in the murine BAT versus WAT but only slightly more abundant in the human BAT versus WAT (Svensson et al., [@B56]).

Notably, the degree of white adipocyte responsiveness to the selective β3 adrenergic agonists BRL37344 and CGP12177 (relative to isoproterenol) was shown to inversely correlate with animal size. Rats and hibernators such as golden hamsters and dormouse were shown to be hyper-responders, medium-size mammals such as rabbits and dogs were weak-responders, and monkeys and men were reported to be either very weak or non-responders (Lafontan and Berlan, [@B33]).

Another distinguishing parameter in the lipid metabolism of mice and men is the predominant lipoprotein class carrying cholesterol: low-density lipoproteins (LDL) in humans, high-density lipoproteins (HDL) in rodents (Vitic and Stevanovic, [@B63]).

Finally, the shared amino acid identity of mouse and human UCP1 is less than 80%. The rodent UCP1 kinetics has been extensively studied in a variety of expression systems. Isolated mitochondria, liposomes, lipid bilayers, yeast, cell lines, and tissue have been used. A comparative table displaying the results for the membrane potential, UCP1 protein concentration, and the rates of proton transport of each system can be found in the review by Hirschberg et al. ([@B21]). In contrast, no study on human UCP1 kinetics has been performed to date.

In view of such species-dependent variations, studies ultimately aimed at being translated into the clinics must ideally be conducted on human cellular models of white and BAT whenever available. Additionally, the specific lack of studies on human UCP1 kinetics urgently calls for a human brown adipocyte cell line (or precursor cell line) with the obvious advantage of allowing this system to be characterized in its native environment.

Human adipocyte-like cell lines
-------------------------------

Biopsies of spontaneous tumors have provided a source of immortalized precursor cells that can be differentiated into white adipocytes *in vitro* (Table [1](#T1){ref-type="table"}). The Lisa-2 cells (Wabitsch et al., [@B65]) and the LS-14 cells (Hugo et al., [@B27]) were obtained from patients with liposarcoma. The AML-I cells (Torii et al., [@B59]) were derived from peripheral blood mononuclear cells from a patient with acute myeloid leukemia. Another white pre-adipocyte cell line, which continuously proliferates in culture, was obtained from a patient with the Simpson--Golabi--Behmel syndrome (Wabitsch et al., [@B64]). The Chub-S7 cell line (Darimont et al., [@B12]) was derived from subcutaneous white adipose and immortalized with the human telomerase reverse transcriptase (hTERT) and the papillomavirus E7 oncoprotein (HPV-E7; Table [1](#T1){ref-type="table"}).

###### 

**Human adipocyte cell lines**.

  Cell line                       White or brown   Immortalization method                                                           Reference
  ------------------------------- ---------------- -------------------------------------------------------------------------------- ----------------------------------------------------
  Lisa                            White            Spontaneous tumor (liposarcoma)                                                  Wabitsch et al. ([@B65])
  LS-14                           White            Spontaneous tumor (liposarcoma)                                                  Hugo et al. ([@B27])
  AML-1                           White            Spontaneous tumor (leukemia)                                                     Torii et al. ([@B59])
  SGBS                            White            Simpson--Golabi--Behmel syndrome                                                 Wabitsch et al. ([@B64])
  Chub-S7                         White            Telomerase reverse transcriptase and papillomavirus E7 oncoprotein transformed   Darimont et al. ([@B12])
  SVF from supra-clavicular fat   Brown\*          None                                                                             Lee et al. ([@B35])
  Primary stem cells              Brown\*          None                                                                             Morganstein et al. ([@B36]), Elabd et al. ([@B13])
  PAZ6                            Brown\*          SV40 T and t antigens transformed                                                Zilberfarb et al. ([@B69])

*\*Expressing UCP1*.

In contrast to the general availability of peripheral subcutaneous or omental tissues and of occasional occurrence of liposarcomas (Wibmer et al., [@B67]), hibernoma, or pheochromocytoma tumors associated with well-localized BAT depots are extremely rare (Lath et al., [@B34]), probably explaining why there are no reports on immortalized cell lines of such origin in the literature.

Stromal vascular cells obtained from adult human biopsies following F-DG PET/CT scans were recently shown to differentiate *in vitro* into UCP1-positive adipocytes. This study confirms unequivocally the presence of potential BAT-cell precursors in the supraclavicular region in humans independent of their F-DG PET/CT status, as both PET-negative and positive biopsies provided UCP1-positive cells (Lee et al., [@B35]).

Although human primary stem cells that differentiate into brown adipocytes *in vitro* can now be routinely obtained, an obvious caveat is that they cannot be propagated beyond a few cell passages and cannot be easily compared between individuals due to expected genetic variations.

The PAZ6 Cell Line
==================

Origin
------

The PAZ6 cell line was obtained from the vascular stromal fraction from human infant BAT and immortalized through transfection with the genes coding for the SV40 T and t antigens under the control of the vimentin promoter (Zilberfarb et al., [@B69]). It fulfills the condition of an immortalized human cell model with the ability to differentiate into brown adipocytes in culture.

UCP1 detection
--------------

Uncoupling protein 1 was shown by qPCR and Northern Blot to be present in differentiated PAZ6 cells and to be further induced by norepinephrine (NE; Figure [1](#F1){ref-type="fig"}). Presence of this BAT-exclusive protein is a required criterion for defining BAT.

![**Expression of the UCP1 gene in PAZ6 pre-adipocytes and adipocytes**. PAZ6 cells were differentiated as described in the legend of Figure [1](#F1){ref-type="fig"}. (a) RT-PCR analysis of the *UCP* gene expression: lane 1, PAZ6 pre-adipocytes; lane 2; PAZ6 differentiated adipocytes; lane 3; PAZ6 differentiated adipocytes incubated with 10--5 M norepinephrine for 4 h; lane 4, positive control: human brown adipose tissue from a patient with pheochromocytoma; + and − symbols indicate the presence or absence of reverse transcriptase. Each lane contained 200 ng total RNA. Size of the amplification product: 498 base pairs. cDNAs were amplified for 33 cycles (Zilberfarb et al., [@B69]).](fendo-03-00013-g001){#F1}

This UCP1-expressing human cell line may enable the characterization of human UCP1 in its "normal" environment and may help support the concept that "BAT can counteract obesity in humans." However immortalization and advanced passaging can alter the cell phenotype (Hirschberg et al., [@B21]). Uncoupling activity may be down-regulated upon continuous propagation of cells *in vitro* since UCP-mediated thermogenesis results from physiologic adaptation in whole animal, in a sympathetic-dependent manner (Festuccia et al., [@B16]). Drugs that promote UCP1 gene expression have been successfully used to overcome this *in vitro* caveat.

Technical issues aside, UCP1 concentration in human BAT may be several fold lower than in rodents (Lean et al., [@B24]), predicting low UCP1 in future human cellular models. Proper normalization will be essential to correct species-associated differences in absolute UCP1 content and total levels should be accounted for in estimations concerned with metabolic significance.

Characterization of the human brown adipocyte cell line PAZ6
------------------------------------------------------------

Continuous characterization of the PAZ6 brown adipocytes since their initial development in 1997 (Zilberfarb et al., [@B69]) has revealed the expression of several key adipogenic markers. The cells have also been employed as an *in vitro* model for the study of adipose-specific processes, such as leptin secretion and nuclear receptor-dependent gene expression (Bailleul et al., [@B1]; Grosfeld et al., [@B18]; Oberkofler et al., [@B41], [@B42],[@B43]) in addition to simply being utilized as a "host" *in vitro* vessel for studies of generic cellular processes (Esterbauer et al., [@B14], [@B15]; Hazan et al., [@B19]; Tang et al., [@B57]). These additional findings and their relevance to a better understanding of (brown) adipose tissue biology are discussed here.

Adipogenic markers
------------------

The 14 days differentiation cocktail described by Zilberfarb et al. ([@B69]) was shown to up-regulate the genes for β~1~, β~2~, and β~3~ adrenergic receptors (β-AR), hormone sensitive lipase (HSL), lipoprotein lipase (LPL), adipsin, glucose transporters 1 and 4 (GLUT 1 and 4), and leptin. The mRNA's of adipocyte-positive TNF-α receptors, TNFR1 and TNFR2 are also detected in confluent PAZ6 (Zilberfarb et al., [@B70]). The expression of such genes parallels the progressive accumulation of multilocular fat stores in the cytosol of PAZ6 cells (Figure [2](#F2){ref-type="fig"}; Zilberfarb et al., [@B69]) and display expression kinetics comparable to human primary adipocytes (Figure [3](#F3){ref-type="fig"}).

![**Multilocular lipid accumulation in PAZ6 adipocytes upon differentiation**. **(A)** PAZ6 pre-adipocytes in culture. **(B)** Differentiated PAZ6 adipocytes. Differentiation was carried out for 3 weeks in propagation medium supplemented with 1 nM T~3~, 850 nM insulin, 100 nM dexamethasone, and 1 μM pioglitazone (Zilberfarb et al., [@B69]).](fendo-03-00013-g002){#F2}

![**Comparison of the expression of adipocytes markers during the course of differentiation of PAZ6 cells and human primary adipocytes from subcutaneous adipose tissue of the abdominal region**. Cells were differentiated as described in the legend of Figure [1](#F1){ref-type="fig"}. The expression of adipocyte markers was evaluated by RT-PCR as described by Zilberfarb et al. ([@B69]).](fendo-03-00013-g003){#F3}

Treatment with the β~3~-AR agonist CGP12177A, a β~1~ and β~2~ antagonist (Blin et al., [@B4]), promotes glycerol release by PAZ6 adipocytes at levels comparable to forskolin, NE, or isoproterenol (Zilberfarb et al., [@B69]), confirming that coupling of the β~3~-AR to lipolysis is intact in PAZ6. The β~3~ is the predominant AR subtype detected in PAZ6 cells (75% of the total β-AR binding; Jockers et al., [@B30]), an important feature also seen in the membranes of brown adipocytes obtained from a BAT capsule growing around a pheochromocytoma adrenal gland tumor. Similar to brown adipocytes and differentiated peritumoral precursors pre-treated with NE for several hours, PAZ6 β~3~-AR signaling undergoes desensitization (Jockers et al., [@B30]), in part due to the down-regulation in receptor number (Jockers et al., [@B30]).

The melatonin receptor 1b isoform (MT2), earlier found in BAT and WAT, is expressed in PAZ6 cells (Brydon et al., [@B6]). There, melatonin doses around the physiological IC~50~ were shown to be inhibitory to forskolin-dependent rise in cyclic adenosine monophosphate (cAMP; Brydon et al., [@B6]).

Also resembling other adipocyte *in vitro* models (Tontonoz and Spiegelman, [@B58]), PAZ6 differentiation was shown to respond to the thiazolidinediones: naphthylazo (5-\[2-(2-naphthylmethyl)-5-benzofuranylmethyl\]-2,4-thiazolidinedione) or pioglitazone (5-\[4-\[2-(5-ethyl-2-pyridyl)ethoxy\]benzyl\]-2,4-thiazolidinedione) with up-regulation of the classic adipose-marker adipocyte protein 2 (aP2) and also of the genes coding for the adipogenic-associated proteins--peroxisome proliferator-activated receptor gamma (PPARγ), β~3~-AR, HSL, and uncoupling protein 2 (UCP2; Strobel et al., [@B55]). Moreover, PAZ6 respond to dexamethasone with up-regulation of the fat-metabolism-related genes for CCAAT-enhancer-binding proteins alpha (C/EBPα), PPARγ, LPL, and leptin (Zilberfarb et al., [@B70]) in a dose-dependent manner.

The levels of the adipokine leptin expressed and secreted by PAZ6 were shown to be remarkably comparable to human primary adipose cells. Leptin levels responded to low oxygen concentration culturing or chemically induced hypoxia with a two to threefold induction in expression. The hypoxia-inducible GLUT1 was up-regulated as expected and, not surprisingly, GLUT4, UCP2, and the lipid-processing proteins aP2 and HSL were down-regulated in hypoxic PAZ6 (Grosfeld et al., [@B18]).

The secretion of the leptin mutant R105W transfected in PAZ6 cells was impaired. Its retention by size-exclusion membranes that normally allow the elution of wild-type leptin suggests that the R105W form aggregates in the adipose cell (Boute et al., [@B5]).

PAZ6 cells express the human mRNA splice variant of the leptin receptor gene encoding a protein designated "leptin receptor gene-related protein" (OB-RGRP) distinct from the classic leptin receptor (OB-R; Bailleul et al., [@B1]). OB-RGRP was suggested to negatively regulate the function of the OB-R by decreasing its cell surface expression levels (Couturier et al., [@B10]). Hence, its expression might regulate leptin activity with consequent implications for the biology of PAZ6 cells.

Nuclear receptors
-----------------

In PAZ6, peroxisome proliferator-activated receptor gamma co-activator 1-alpha (PGC1α)-dependent increase in UCP1 gene expression by retinoic acid (RA) or TZD (Oberkofler et al., [@B41]) has been observed, while a PPARα-specific agonist WY14,643 failed to regulate the expression of the UCP1 gene unless combined with RA (Oberkofler et al., [@B41]).

The UCP1 promoter is known to contain an enhancer region 3.7 kb upstream of the transcription initiation site containing several putative nuclear receptors (Cao et al., [@B8]; Collins et al., [@B9]). Specifically, a 221 bp region, 2.5 kbp upstream of the start codon, contains a PPARγ (PPRE), *cis*-acting cAMP (CREB), and thyroid hormone (TRE) response elements. Retinoic acid receptor (RAR) was also described to mediate increased UCP1 expression, even though RA levels do not rise in the cold. PPARα is regulated by cold and has been associated with increased UCP1 levels (Cao et al., [@B8]; Collins et al., [@B9]). The finding that the latter was not sufficient for the UCP1 gene activation is suggestive of the complex interplay between the several promoter receptors, transcriptional factors and cofactors. To explain the lack of effect of WY14,643 alone, it was hypothesized that -- in non-stimulated states -- PPARα binds a putative repressor forming a complex that could dissociate in the presence of p38 mitogen-activated protein kinases (p38 MAPK) signaling. Confirming this hypothesis, Oberkofler et al. ([@B41]) showed that a MAPK-specific inhibitor (SB202190) completely abolished the stimulatory response seen in the PGC1α-dependent UCP1 promoter activity of cells treated with the combination RA/WY14,643 (Oberkofler et al., [@B41]).

Inhibition of the p38 MAP kinase signaling pathway with the same inhibitor was shown to impair PAZ6 adipocyte differentiation in an independent study (Zilberfarb et al., unpublished results; Figure [4](#F4){ref-type="fig"}).

![**Effect of inhibition of p38 MAP kinase on the expression of adipocyte differentiation markers in PAZ6 cells**. PAZ6 pre-adipocytes (Pread) were cultured during 1 week in differentiation medium containing or not of the p38 inhibitor SB2022190 (10 mM). mRNA was then extracted and the expression of adipocyte differentiation markers was evaluated by RT-PCR as described by Zilberfarb et al. ([@B69]).](fendo-03-00013-g004){#F4}

The ratio of sterol regulatory element-binding protein 1a/1c (SREBP1a/1c) in cells lines compared to primary tissues (spleen excluded) such as liver, adipose, adrenals, and others is inverted (Shimomura et al., [@B54]). This inverted pattern was also detected in PAZ6 cells, where the ratio SREBP1a/1c equals to 14. Predominance of the 1a isoform has been also found in 3T3-L1 cells where the 1c isoform is in fact, undetectable. 3T3-L1 differentiation results in an additional several fold increase in SREBP1a levels, with SREBP1c remaining below the detection threshold. In PAZ6 co-transfected with PGC1a/SREBP1c Luc-reporter, treatment with liver X receptor (LXR)/retinoid X receptor (RXR) agonists cells increased the activity of the SREBP1c promoter (Oberkofler et al., [@B43]), leading to the interpretation that low LXR activity, due to low PGC1α content might be the cause of the SREBP isoform ratio inversion of cell lines. The isoform 1a is much more active in stimulating transcription from SRE-1-containing promoters and was described to stimulate cholesterol metabolism-related genes (HMG CoA synthase, HMG CoA reductase, and LDL receptor) with greater ability than fatty acid metabolism-related ones (fatty acid synthase, acetyl CoA carboxylase, and LPL). This predominance of SREBP1a *in vitro* could be attributed to the elevated cholesterol demand of rapidly proliferating cultured cells, a relationship yet to be investigated.

Comparative cDNA microarray analysis versus lisa-2
--------------------------------------------------

A comparative microarray study between the PAZ6 and Lisa-2 cell lines (and between those and WAT) was performed by Van Beek et al. ([@B60]). The authors firstly identified, through a cDNA subtraction strategy, the 30 most discriminating genes between WAT and two non-adipose tissues (lung and colon). Subsequently, by comparative cDNA microarray analysis, the percent expression of those cDNA's by PAZ6 and Lisa-2 cells relative to WAT was calculated. In both cell lines most of those highly discriminating, adipose-enriched genes were detected, several of which were, as expected, up-regulated by differentiation. Importantly, the gene expression pattern of the Lisa-2 cell line was reported to resemble WAT more closely than the PAZ6 (Van Beek et al., [@B60]). However, as a cDNA library of BAT was not established in parallel to WAT, the particular distinction between the respective white and brown features of the Lisa-2 and the PAZ6 cells was not addressed. Nonetheless, the study confirmed the similarities among the human adipose cell lines and the primary tissue and helped differentiate genes expressed in all three adipocyte-derived cells from those found in non-adipose tissues.

Others adipose tissue features of PAZ6 cells
--------------------------------------------

In agreement with two other studies on the effects of the steroid hormone dehydroepiandrosterone (DHEA) on human pre-adipocytes, the proliferation of PAZ6 cells, tested in parallel with 3T3-L1 and human primary pre-adipocytes, was significantly inhibited (Rice et al., [@B48]). The effect was observed in both cell lines under a 24 h exposure of 100 nM to 100 μM DHEA. Intra-adipocyte DHEA concentration is an order of magnitude higher than the circulating levels which are within the nanomolar range, so the concentrations used in those test were within physiological levels (Rice et al., [@B48]).

The transcriptional activity of the wild-type or a variant UCP2 promoter was analyzed in PAZ6 cells. The common G/A polymorphism was shown to be associated with a 22% increase in transcriptional activity in differentiated but not in PAZ6 pre-adipocytes (Esterbauer et al., [@B15]).

The glycoprotein 130 ligands oncostatin M, interleukin-6, and cardiotrophin-1 increased several fold the secretion of the vascular endothelial growth factor (VEGF) in PAZ6 pre-adipocytes (4, 3.5, and 3-fold, respectively) and adipocytes (3.5, 2, and 2-fold, respectively), in line with findings obtained from adipose tissue *ex vivo*, subcutaneous and visceral pre-adipocytes (Rega et al., [@B47]).

Future Perspectives
===================

Uncoupling protein 1 confers to mammals the ability to functionally cope with low ambient temperatures (Nicholls, [@B40]; Klingenspor et al., [@B32]). Thought to have first appeared in placental mammals, this transporter was later found to possess orthologs in marsupials and even ectotherm vertebrates (Nicholls, [@B40]; Klingenspor et al., [@B32]). Whether a thermogenic function holds true in these other vertebrates requires direct testing. Nevertheless, in the adequately clothed adult human, this perhaps dispensable thermogenic capacity has recently been recognized as an attractive anti-obesity target. Its potential to increase energy dissipation with no physical effort strongly appeals to the medical community, as compliance with standard diet and exercise recommendations is generally low. The benefits of increased BAT capacity further extend to improved clearance of circulating glucose and lipids (Bartelt et al., [@B2]; Orava et al., [@B44]) in a fashion analogous to the contracting skeletal musculature (Ivy, [@B29]).

It is, however, important to distinguish BAT mass from BAT-derived energy expenditure increase. While in cold adaptation, energy expenditure raises in parallel with BAT mass (Rothwell and Stock, [@B51]; Ouellet et al., [@B45]), the manipulation of BAT mass through specific drugs or genetic interventions can only translate into increased energy expenditure if all the components of the tissue's thermogenic machinery are active. Some of these components are yet to be uncovered.

A human brown adipose cell model, such as the PAZ6 cells, could become an essential tool to address these relevant questions: what conditions contribute to persistence of the "BAT-like" phenotype or protection from apoptosis? What factors stimulate nutrient catabolism and subsequent UCP1-mediated proton leak? What are the signaling pathways involved in thermogenic activation? Are there highly specific compounds with agonistic activity for such pathways? What constitutes the BAT "secretome"? Can BAT-cells be successfully engineered for transplantation in humans? Would individuals receiving BAT surgically become less cold-sensitive as possibly are those who naturally possess larger BAT depots?

Conclusion
==========

The PAZ6 studies compiled to date include a significant list of BAT-specific characteristics (Table [2](#T2){ref-type="table"}). The biological significance of the UCP1 levels expressed by differentiated PAZ6 adipocytes deserves to be better explored. The proper assessment of uncoupled respiration in PAZ6 cells will provide definite support to the relevance of the gene expression and morphology data. Continuous characterization will further support the use of PAZ6 cell line as a *bona fide* human brown adipocyte model and increase the number of its potential applications.

###### 

**Brown adipose-specific, adipose-specific, and other PAZ6 cells features**.

  PAZ6 Brown adipose features                                             Reference
  ----------------------------------------------------------------------- -------------------------------------------
  UCP1 expression                                                         Zilberfarb et al. ([@B69])
  Multilocular fat accumulation                                           Zilberfarb et al. ([@B69])
  β~3~-AR predominance                                                    Jockers et al. ([@B30])
  **PAZ6 ADIPOSE FEATURES**                                               
  aP2, PPARγ, C/EBP-α, HSL, LPL, leptin, GLUT1, and GLUT4 presence        Zilberfarb et al. ([@B69])
  β~1~, β~2~, and β~3~-AR expression and β-adrenergic-coupled lipolysis   Zilberfarb et al. ([@B69])
  PPARγ-sensitive differentiation                                         Strobel et al. ([@B55])
  Melatonin receptor expression (isoform MT2, found in BAT)               Brydon et al. ([@B6])
  **OTHER PAZ6 FEATURES**                                                 
  Transfectable                                                           Oberkofler et al. ([@B41], [@B42],[@B43])
  Anti-proliferative response to DHEA                                     Rice et al. ([@B48])
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